Accessibility of SGLT-2 Inhibitors in Hubei Province Based on WHO/HAI Standard Survey Method
Objective To investigate the availability of sodium-dependent glucose transporters 2(SGLT-2)inhibitors in Hubei Province,and to provide reference for drug clinical use and policy formulation.Methods According to the standard survey method of World Health Organization/Health Action International(WHO/HAI),the accessibility of SGLT-2 inhibitors in medical institutions in Hubei Province was investigated and evaluated,and key person interviews were used to analyze the key factors affecting the availability and affordability of SGLT-2 inhibitors.Results From 2018 to 2023,the specification and availability of SGLT-2 inhibitors showed an overall increasing trend,and was generally higher in tertiary hospitals than in secondary hospitals.Dapagliflozin had the best availability,which increased from poor availability(<25%)to good availability(>75%)in hospitals from 2018 to 2023,followed by empagliflozin,and the availability of other drugs was relatively poor.The main factors affecting the availability were drug price,whether drugs were included in medical insurance and whether drugs were collected.From the perspective of affordability,SGLT-2 inhibitors were generally poor(the cost of 30 d treatment of drugs was more than 1 times the minimum daily wage),but the domestic prices of some generic drugs such as canagliflozin,ertugliflozin and empagliflozin were lower than the international reference prices.The main factors affecting affordability were medical insurance coverage and reimbursement ratio,drug prices and patient and family income.Conclusion The price,availability and affordability of SGLT-2 inhibitors in Hubei Province needs to be further improved.With the promotion of the therapeutic status of such drugs and the increase in clinical demand,it is expected that relevant departments can promote adjustment in terms of policies such as collection,medical insurance,essential drugs and drug research and development and production.
SGLT-2 inhibitorsAvailabilityAffordabilityOriginal drugGeneric drug
NETL
NSTL
万方数据
